Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cardiac steroid antagonists and related methods

A sequential, non-natural technology, applied in chemical instruments and methods, biochemical equipment and methods, pharmaceutical formulations, etc., which can solve problems such as loss of specificity

Active Publication Date: 2020-03-24
MARSHALL UNIV RES
View PDF47 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Consequently, most inhibitors developed to target the Src kinase domain may also interact non-specifically with other protein kinases, which in turn leads to the observed loss of specificity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cardiac steroid antagonists and related methods
  • Cardiac steroid antagonists and related methods
  • Cardiac steroid antagonists and related methods

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0077] Example 1 - The second cytoplasmic domain of Na / K-ATPase as a modulator of the Src SH2 domain.

[0078] Na / K-ATPase directly interacts with Src kinases through two domain-domain interactions (Tian, ​​Cai et al. 2006; Ye, Li et al. 2011). Specifically, the second cytoplasmic domain (CD2) of Na / K-ATPase binds the Src SH2 domain, and the N domain of Na / K-ATPase binds the Src kinase domain. Conjugation of cardiotonic steroids such as ouabain disrupts N domain / kinase domain interactions, whereas CD2 / SH2 interactions are usually constitutive. In this regard, because CD2 binds the Src SH2 domain, and the SH2 domain functions in targeting Src kinases to specific signaling complexes, it is believed that ectopically expressed CD2 will act as the Na / K-ATPase / Dominant-negative mutant of the Src receptor complex and thereby inhibits ouabain-mediated cell signaling. To test this notion, CD2 was expressed in LLC-PK1 cells as a yellow fluorescent protein (YFP) fusion protein, and ...

Embodiment 2

[0081] Example 2 - Development of Peptide Antagonists for Disruption of CD2 / SH2 Interaction.

[0082] In light of the foregoing findings, experiments were then performed to develop highly specific peptide antagonists for disrupting the CD2 / SH2 interaction to inhibit cardiac steroid-mediated signaling in cells. It has been observed that the Src SH2 domain displays preferential binding to phosphorylated tyrosine residues. Such as Figure 4A CD2 from the α1 subunit of Na / K-ATPase (mammals; SEQ ID NO: ) contains only a single tyrosine at position 260 (in unmodified Na / K-ATPase), as shown in To determine whether this tyrosine can be phosphorylated in CD2 expressing cells. Such as Figure 4B As depicted in , CD2 can be phosphorylated when it is expressed in cells. Figure 4C It was further shown that in normal LLC-PK1 cells, tyrosine 260 of the full-length Na / K-ATPase was phosphorylated. Furthermore, this phosphorylation can be stimulated by ouabain, since ouabain increases p...

Embodiment 3

[0083] Example 3 - Affinity of Peptide Antagonists

[0084]A peptide derived from CD2 called CD2C2 (see, e.g., SEQ ID NO: 1 in PCT Application No. PCT / US2011 / 021130, incorporated herein by reference) was previously shown to be effective when assayed using a reconstituted in vitro system Glycoside antagonists. In view of the above new findings and previous information on CD2C2, experiments were then performed to assess whether the same peptide (see SEQ ID NO: 1 of the present application) that Y260 is phosphorylated has more Higher affinity. Briefly, to perform these experiments, and to make the peptide permeable to cell membranes, the peptide of SEQ ID NO: 1 was attached to a TAT tag as previously done with other Na / K-ATPase-derived peptides (Li, Cai et al. 2009). The new peptide was designated pNaSH2 (SEQ ID NO:3). For comparison and contrast, CD2C2 with the same TAT tag was also synthesized and designated NaSH2 (SEQ ID NO:4) to indicate that the peptide was not phospho...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides non-naturally occurring peptides that act as Src SH2 domain antagonists of cardiac steroids. The present invention also provides a pharmaceutical composition comprising the peptide and a vector encoding the peptide. The present invention further provides a method for treating Src-related diseases and reducing Src activity in cells, and the method comprises administering or contacting the cells with an effective amount of the peptide.

Description

[0001] related application [0002] This application claims priority to US Provisional Application Serial No. 61 / 974,252, filed April 2, 2014, the entire disclosure of which is hereby incorporated by reference. [0003] Government interests [0004] This invention was made with government support under Grant No. HL 109015 awarded by the National Institutes of Health. The government has certain rights in this invention. technical field [0005] The presently disclosed subject matter relates to cardiotonic steroid antagonists and methods of use thereof. In particular, the presently disclosed subject matter relates to cardiac steroid antagonists comprising peptides that act as antagonists of the Src SH2 domain of cardiac steroids and methods of using the peptide antagonists to treat Src related diseases such as cancer and cardiovascular disease. Background technique [0006] Cardiotonic steroids are a group of compounds that bind to and inhibit Na / K-ATPase, the protein respo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K14/47C07K7/08G01N33/573
CPCA61K38/00A61K38/46C07K7/08C07K2319/00C07K2319/01C12N9/14C12Q1/485C12Q1/50C12Y306/03009G01N33/5044G01N33/573G01N2333/3153G01N2333/3156G01N2333/91G01N2333/9723A61K45/06
Inventor 谢子建穆米塔·班纳吉
Owner MARSHALL UNIV RES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com